| 1 |
29545419 | Correction: The Multikinase Inhibitor Sorafenib Potentiates TRAIL Lethality in Human Leukemia Cells in Association with Mcl-1 and cFLIPL Down-regulation. | 2018 Mar 15 |
1 |
| 2 |
30066934 | Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma. | 2018 Oct |
4 |
| 3 |
29137334 | The coffee diterpene kahweol enhances sensitivity to sorafenib in human renal carcinoma Caki cells through down-regulation of Mcl-1 and c-FLIP expression. | 2017 Oct 10 |
3 |
| 4 |
20071162 | The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. | 2010 Mar |
1 |
| 5 |
19483104 | Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. | 2009 Aug |
2 |
| 6 |
19483105 | BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. | 2009 Aug |
4 |
| 7 |
20038816 | Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. | 2009 Dec |
1 |
| 8 |
18765530 | Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. | 2008 Sep 1 |
3 |
| 9 |
17909059 | The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. | 2007 Oct 1 |
4 |